CCL2 and Parkinson disease: It has been shown that PD patients with GBA mutations have increased plasma levels of some inflammatory molecules, including some monocyte markers (such as IL-8, MCP1, stem cell factor, pulmonary and activation-regulated chemokine (PARC) and macrophage inflammatory protein 1α (MIP1α)) β [155], in comparison with sporadic PD cases.